Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03912064 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 1
Development phase
25
Enrollment target
2
Study locations

NCT03912064 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03912064, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
25 participants
Enrollment target
2
Study locations

Study Summary

In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF).

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia Myelofibrosis Myeloproliferative Neoplasms

Interventions

  • DRUG Ipilimumab
  • BIOLOGICAL CD25hi Treg depleted DLI

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2019-07-10
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03912064

The ClinicalTrials.gov registry entry for NCT03912064 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (78% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Ipilimumab is the first listed.

NCT03912064 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03912064 about?

NCT03912064 is a clinical study titled "A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT". In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myelopr...

What is the current status of trial NCT03912064?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-07-10. Estimated completion is 2026-12-31.

What conditions does trial NCT03912064 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasms.

What interventions are being tested in trial NCT03912064?

The interventions under investigation include: Ipilimumab (DRUG), CD25hi Treg depleted DLI (BIOLOGICAL).

Who is sponsoring clinical trial NCT03912064?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03912064 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.